REVIEWER

Rodolphe Thiébaut INSERM, France
Author of a systematic review on EBV vaccine Coordinator of EBOVAC2 consortium for the development of Ad26+MVA vaccine in collaboration with Janssen REVIEW RETURNED 08-Mar-2019 GENERAL COMMENTS This is a protocol for a systematic review of the « effects » of Ebola vaccines. This review is relevant in the context of the development of several vaccine candidates while Ebola epidemics are still occurring.
The introduction could be improved by flagging any systematic reviews/meta-analyses already published such as Gross et al.
International Journal of Infectious Diseases 74 (2018) 83-96. It would help to underline the originality of the present review even though an update is already interesting by itself.
A clarification of the wording of the objectives would be helpful. What vaccine effect means? The reader gets a part of the answer when reading later the primary outcome (incidence of EBV disease). Therefore, it worths to specify that the objective of the study is to assess the vaccine efficacy on the protection against the EBV disease, the immune response and side effects.
The authors chose to select any study whatever the design. However, the information provided by RCT will be much different from observational designs and will already by very heterogeneous. Therefore, a stratification according to design could be considered.
Other comments: in the search methods: provide the exact algorithm for publication database research Data extraction: explain how you are going to deal with incomplete information (e.g. getting standard deviation from range…) « Measures of treatment effect »: the description could be improved that is geometric mean vs mean for ab titres, OR in case of case control studies… Study participants: state in Humans as presumably NHP studies are not eligible.
VERSION 1 -AUTHOR RESPONSE
Responses to comments and additional changes made by the authors A. Major comments 1) Currently, only one candidate vaccine rVSVΔG-ZEBOV-GP has been proved to efficient in phase III trials to protect human from Ebola diseases. How to evaluate the effects of other Ebola vaccines with the evidence of protection missing? Do the author consider to involve the animal challenge studies into the evaluation at the meantime?
Response: We thank you for this comment, however we will not include animal studies in this review. We will only focus on Ebola trials in humans that have been conducted to date. We will synthesise, analyse and report on the safety and efficacy of Ebola vaccine from identified Ebola trials
2)
The duration of the immune responses elicited by the Ebola vaccines is uncertain since the follow-up periods of most of the trials were short. The immune responses could be various significantly at different follow-up times. Plus, the surrogates of protection are not defined, the authors should consider how to deal with the uncertainty of the immune responses and the comparisons among different candidates.
Response: Thank you for highlighting this important point. We have addressed this point in the section of "assessment of heterogeneity" Page 11; line 276-278, we will also consider degree of risk of bias in the studies, outcome measurement process, and assess variation in treatment effects including immune responses.
3)
Most of the trails of the candidate vaccines were still in the early phases, only evaluated in healthy adults. There were limited information or data on the safety, immunogenicity, or effects of the vaccines in children, HIV-positive individuals, pregnant women and other special populations.
Response: We thank you for this important observation. It is noted that data on the safety, immunogenicity, or effects of the vaccines in children, HIV-positive individuals, pregnant women and other special populations is limited. However, on page 11, line 292-295, we have noted that we will perform sub group analysis should these special populations be identified in the included studies.
4)
The effects of Ebola vaccine are nearly impossible to investigate without an Ebola outbreaks. And the cross protection of the candidate vaccines against Ebola virus species other than Zaire species is even harder to observe.
Response: Thank you for this important comment, we have considered incorporating this comment in the discussion upon analysis and reporting of results in the systematic review.
5)
The introduction could be improved by flagging any systematic reviews/meta-analyses already published such as Gross et al. International Journal of Infectious Diseases 74 (2018) 83-96. It would help to underline the originality of the present review even though an update is already interesting by itself.
Response: Thank you. We have improved the introduction in page 5 to rephrase line 130-132 to include the suggested systematic review "There have been several trials investigating the effects of candidate Ebola vaccines including a systematic review of Ebola vaccine development which reviewed Ebola vaccine studies to assess factors associated with antibody response variability in humans, however there is no collective evidence of what the effects of the Ebola vaccines are"
6)
Response: Thank you. We have added the suggestion in page 6; line 139-140.
7)
Response: Thank you for the comment, we have considered this comment and added the suggested wording and rephrased in page 11; line 282-284. "We will stratify analyses by study design and pool data from studies with identical designs, candidate vaccines and outcomes using the fixed-effect Mantel-Haenszel model for meta-analysis" B.
Other comments 8) in the search methods: provide the exact algorithm for publication database research
Response: Thank you we have added the exact algorithm in the search methods section, page 8; line 202 9) Data extraction: explain how you are going to deal with incomplete information (e.g. getting standard deviation from range…) Response: Thank you. We have accounted for incomplete information on the page 10; line 269-271, "If there is missing data in the included studies, we will assess whether the missing data is related to outcomes and contact the trial authors for more information. We will perform intention to treat analysis to account for missing data of important outcomes" and in page 12; line 303-304, "we may use imputation and perform sensitivity analysis to assess the impact of the missing data"
10)
Measures of treatment effect: the description could be improved that is geometric mean vs mean for ab titres, OR in case of case control studies…
